Telix (TLX) Files 6-K Revealing $240M Q2 Sales Surge

Rhea-AI Filing Summary

Telix Pharmaceuticals Limited (TLX) has furnished a Form 6-K announcing its Q2 2025 top-line result. The company disclosed US$240 million in quarterly revenue, a 63% year-over-year increase, via an accompanying ASX press release (Exhibit 99.1). No additional income-statement, cash-flow or forward-guidance metrics are included in this filing. The document serves primarily to place the Australian announcement into the U.S. market via the SEC.

While the strong revenue growth signals continuing commercial traction for Telix’s radiopharmaceutical portfolio, investors will need to consult the full press release or upcoming results for margin, profit and outlook details. The filing was signed by Company Secretary Genevieve Ryan on 22 July 2025.

Positive

• 63% YoY revenue growth to US$240 million demonstrates significant commercial momentum.
• Consistent SEC compliance via Form 6-K keeps U.S. investors informed alongside ASX market.

Negative

• No profitability, margin or guidance metrics disclosed, limiting full financial assessment.

Insights

Equity Research Analyst

TL;DR – 63% YoY revenue jump is clearly positive, but filing lacks profit, margin or guidance data.

The headline US$240 million Q2 revenue underscores rapid uptake of Telix’s lead product Illuccix in the U.S. and initial EU launches. A 63% YoY growth rate materially outpaces both radiopharma peers and broader med-tech averages, implying share-gain momentum. However, without gross-margin disclosure, investors cannot gauge operating leverage or sustainability of growth. Still, the magnitude of top-line acceleration justifies a constructive near-term view.

Biotech Industry Specialist

TL;DR – Material revenue beat highlights commercial execution; data breadth limited.

A US$240 million quarter places Telix among the fastest-scaling commercial biotechs. The figure suggests annualised sales approaching US$1 billion, supporting potential index inclusion and improved capital access. Yet absence of R&D spend or regulatory updates tempers overall impact. Market will await full Q2 statement to confirm profitability trajectory and pipeline investment balance.

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 6-K

REPORT OF FOREIGN PRIVATE ISSUER

PURSUANT TO RULE 13a-16 OR 15d-16 OF

THE SECURITIES EXCHANGE ACT OF 1934

For the month of July, 2025

Commission File Number: 001-42128

Telix Pharmaceuticals Limited

(Translation of registrant’s name into English)

55 Flemington Road

North Melbourne, Victoria 3051, Australia

(Address of principal executive offices)

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.

Form 20-F ☒ Form 40-F ☐

1

INFORMATION CONTAINED IN THIS FORM 6-K REPORT

On July 22, 2025 (Melbourne, Australia), Telix Pharmaceuticals Limited filed an announcement with the Australian Securities Exchange titled “Telix Reports US$240M Q2 Revenue, Up 63% YOY,” a copy of which is attached to this Form 6-K as Exhibit 99.1.

99.1 Press release – July 22, 2025

2

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

	Telix Pharmaceuticals Limited
Date: July 22, 2025	By:	/s/ Genevieve Ryan
		Name: Genevieve Ryan
		Title: Company Secretary

FAQ

What revenue did Telix Pharmaceuticals (TLX) report for Q2 2025?

The company reported US$240 million in Q2 2025 revenue.

How much did TLX's Q2 revenue grow year over year?

Revenue increased by 63% compared with the prior-year quarter.

What SEC form did Telix file on 22 July 2025?

Telix filed a Form 6-K, Report of Foreign Private Issuer.

Does the Form 6-K include profit or EPS figures?

No. The filing only discloses revenue; profitability metrics are not provided.

Where is Telix Pharmaceuticals headquartered?

The company’s principal executive offices are at 55 Flemington Road, North Melbourne, Victoria 3051, Australia.